Administration of neuritin as a novel therapeutic strategy for autoimmune and inflammatory diseases
Molecular Therapy · 2026-08 · 34 (8) · 4879-4902
DOI: 10.1016/j.ymthe.2026.04.059 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2026-08. Verfasst von Ping Wei und 21 weiteren Autor:innen. Beteiligte Einrichtung: Center for Allergic Diseases, Department of Otolaryngology, West China Second University Hospital, Sichuan University, Key Laboratory of Birth Defect…. Hauptthemen laut MEDLINE: Encephalomyelitis, Autoimmune, Experimental, Autoimmune Diseases, Inflammation, Neuropeptides. Die Arbeit nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Shenzhen Science and Technology Innovation Program, National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Autoimmune and inflammatory diseases are characterized by dysregulated T cell-mediated immune responses leading to tissue damage. Despite therapeutic advancements, patients remain resistant to treatment, highlighting the urgent need for alternative therapeutic strategies. Here, we identified neuritin (NRN), an immunosuppressive molecule, capable of restraining effector CD4+ T cell responses and mitigating autoimmune and inflammatory diseases. NRN is downregulated in CD4+ T cells of rheumatoid arthritis (RA) patients, driving T cell-mediated autoimmune pathology. Nrnfl/flCD4Cre mice exacerbate both experimental autoimmune encephalomyelitis (EAE) and dextran sulfate sodium (DSS)-induced colitis, characterized by regulatory T cell (Treg) depletion and expansion of interferon (IFN)-γ+ and interleukin (IL)-17+ pro-inflammatory cells. Mechanistically, NRN selectively binds to cannabinoid receptor 2 (CB2), but not to CB1, specifically through its threonine residues at positions T78 and T81. Meanwhile, mice lacking CB2 (CB2-/- or CB2fl/flCD4Cre) exhibit worsened colitis, with an increased IFN-γ+ and IL-17+ cells, mirroring the Nrnfl/flCD4Cre phenotype. T cell-specific Nrn knockin (NrnKI/KICD4Cre) or exogenous NRN administration ameliorated disease severity in multiple autoimmune models, including DSS-induced colitis, IMQ-induced psoriasis, and collagen-induced arthritis, by promoting Treg expansion and suppressing IFN-γ+ and IL-17+ pro-inflammatory cells. However, these protective effects of NRN were abolished in CB2-deficient mice. Overall, NRN is an immunosuppressive molecule with therapeutic potential in autoimmune and inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Allergic Diseases, Department of Otolaryngology, West China Second University Hospital, Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Min…
- Faculty of Pharmaceutical Sciences, Shenzhen University of Advanced Technology (SUAT), No. 1 Gongchang Road, Guangming District, Shenzhen 518107, China; Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy…
- Department of Rheumatism and Immunology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China; Shenzhen Key Laboratory of Inflammatory and Immune Diseases, Shenzhen, Guangdong, China; Southern University of S…
- Department of Rheumatism and Immunology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China; Shenzhen Key Laboratory of Inflammatory and Immune Diseases, Shenzhen, Guangdong, China.
- School of Life Sciences, Westlake University, Hangzhou, Zhejiang, China.
- Faculty of Pharmaceutical Sciences, Shenzhen University of Advanced Technology (SUAT), No. 1 Gongchang Road, Guangming District, Shenzhen 518107, China.
Förderung
- Shenzhen Science and Technology Innovation Program
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- Science, Technology and Innovation Commission of Shenzhen Municipality
- National Key Research and Development Program of China
- Sanming Project of Medicine in Shenzhen
- Natural Science Foundation of Sichuan Province
Zitieren
APA
Wei, P., Zhang, K., Hu, Y., Gao, X., Hou, Y., Riaz, F., Zhang, Z., He, J., Zhang, M., Li, Y., Li, F., Wang, A., Zhao, T., Zhang, B., Li, X., Jiang, A., Wu, L., Chen, Y. H., Fan, Z., …, & Pan, F. (2026). Administration of neuritin as a novel therapeutic strategy for autoimmune and inflammatory diseases. Molecular Therapy, 34(8), 4879-4902. https://doi.org/10.1016/j.ymthe.2026.04.059
Vancouver
Wei P, Zhang K, Hu Y, Gao X, Hou Y, Riaz F, et al. Administration of neuritin as a novel therapeutic strategy for autoimmune and inflammatory diseases. Molecular Therapy. 2026;34(8):4879-4902. doi:10.1016/j.ymthe.2026.04.059
BibTeX
@article{Wei2026,
author = {Wei, Ping and Zhang, Kaimin and Hu, Yiping and Gao, Xu and Hou, Yingnan and Riaz, Farooq and Zhang, Zhenzhen and He, Juan and Zhang, Miaomiao and Li, Yikui and Li, Fangfang and Wang, Aiting and Zhao, Taowen and Zhang, Biyi and Li, Xingchi and Jiang, Anmei and Wu, Lin and Chen, Youhai H and Fan, Zusen and Huang, Jing and Wang, Qingwen and Pan, Fan},
title = {Administration of neuritin as a novel therapeutic strategy for autoimmune and inflammatory diseases},
journal = {Molecular Therapy},
year = {2026},
volume = {34},
number = {8},
pages = {4879--4902},
doi = {10.1016/j.ymthe.2026.04.059}
}
EUVIMED